摘要
药品的新标准正在形成,旨在通过研究遗传变异关联,以提高个人对药物的反应。由于一系列低投入、高产出的先进技术,药物基因组学这一领域正在迅速发展。在这里,我们概述了使用淋巴母细胞系(LCL)作为人类药物基因组学研究的模式系统的优势和局限性。 这里有广泛的公开可用的资源,如从相关和不相关的人群的全组基因数据中可获得淋巴母细胞系,这消除了药物反应研究的数据基因分型的成本。此外,与人的临床试验或在体内模型系统相比,药物基因组学研究在体外高通量筛选技术下可以很容易地扩展,以适应大样本。 在淋巴母细胞系模型中关联映射是一个重要的组成部分以扩充全组基因数据。在这儿讨论了几种方法,包括多元浓度响应模型、多重检测试验及已成功的“三角模型”来识别候选变体。一旦确定候选基因变异,它们的生物学作用可通过通路分析阐明,可利用siRNA敲除实验来证实其功能。 通过相关和不相关的人口产生的基因组学数据,它的财富是正在创造许多令人兴奋的机会,这将引起对遗传基因和遗传药物反应新的深刻见解。
关键词: 细胞毒素,基因关联映射,基因组广泛的关联分析,淋巴母细胞系,药物基因组学
Current Molecular Medicine
Title:Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model
Volume: 14 Issue: 7
Author(s): J. Jack, D. Rotroff and A. Motsinger-Reif
Affiliation:
关键词: 细胞毒素,基因关联映射,基因组广泛的关联分析,淋巴母细胞系,药物基因组学
摘要: A new standard for medicine is emerging that aims to improve individual drug responses through studying associations with genetic variations. This field, pharmacogenomics, is undergoing a rapid expansion due to a variety of technological advancements that are enabling higher throughput with reductions in cost. Here we review the advantages, limitations, and opportunities for using lymphoblastoid cell lines (LCL) as a model system for human pharmacogenomic studies.
There are a wide range of publicly available resources with genome-wide data available for LCLs from both related and unrelated populations, removing the cost of genotyping the data for drug response studies. Furthermore, in contrast to human clinical trials or in vivo model systems, with high-throughput in vitro screening technologies, pharmacogenomics studies can easily be scaled to accommodate large sample sizes.
An important component to leveraging genome-wide data in LCL models is association mapping. Several methods are discussed herein, and include multivariate concentration response modeling, issues with multiple testing, and successful examples of the ‘triangle model’ to identify candidate variants. Once candidate gene variants have been determined, their biological roles can be elucidated using pathway analyses and functionally confirmed using siRNA knockdown experiments.
The wealth of genomics data being produced using related and unrelated populations is creating many exciting opportunities leading to new insights into the genetic contribution and heritability of drug response.
Export Options
About this article
Cite this article as:
Jack J., Rotroff D. and Motsinger-Reif A., Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811113946
DOI https://dx.doi.org/10.2174/1566524014666140811113946 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Hydrogen Sulphide and Pain
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Current Pharmaceutical Design Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Epithelial-Mesenchymal Transitions and Cancer
Current Genomics Synthesis of Asymmetric 1-Thiocarbamoyl Pyrazoles as Potent Anti- Colon Cancer, Antioxidant and Anti-Inflammatory Agent
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Hedgehog Signal Transduction Pathway
Current Cancer Therapy Reviews PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs
Anti-Cancer Agents in Medicinal Chemistry PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science